Overview: Anti-SLA Antibody TestIntroduction: The Anti-SLA Antibody Test detects antibodies linked to autoimmune liver diseases, which may cause fatigue, jaundice, or abdominal pain. Aligned with 2023 AASLD guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected autoimmune hepatitis.
Other Names: Anti-SLA Assay, Soluble Liver Antigen Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Autoimmune hepatitis testing began in the 1970s with ANA tests. Anti-SLA assays emerged in the 1990s, and by the 2000s, immunoassays improved specificity for liver diseases.
Purpose: Diagnoses autoimmune liver diseases, guides treatment, and monitors disease activity in patients with fatigue, jaundice, or abdominal pain.
Test Parameters: 1. Anti Soluble Liver Antigen
Pretest Condition: Fasting for 10-12 hours required to stabilize antibody levels. Collect serum or saliva after overnight fasting. Report symptoms like jaundice or abdominal pain, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver symptoms, autoimmune disease history, or family history of liver diseases. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for treatment or liver imaging.
Procedural Considerations: Uses an immunoassay to measure anti-SLA antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or immunosuppressants may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm autoimmune hepatitis, prompting immunosuppressive therapy. Negative results may require other liver antibody tests.
Specialist Consultation: Consult a hepatologist for result interpretation. A gastroenterologist referral is advised for advanced cases.
Additional Supporting Tests: ANA test, liver function tests, or liver biopsy to confirm autoimmune hepatitis or assess liver damage.
Test Limitations: False negatives may occur with early disease or immunosuppressive therapy. Results require clinical correlation.
References: AASLD Autoimmune Hepatitis Guidelines, 2023; Hepatology, Manns MP, 2022.
